NXL
Nexalin Technology, Inc.
NXL lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
NXL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
NXL's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NXL PE Valuation
NXL has no meaningful PE right now: it lost money over the past year.
NXL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect NXL's losses to shrink, with revenue growing.
NXL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.63 | +$6.47 |
| Q2 2026 | -$14.10 | +$9.00 |
| Q1 2026 | -$13.80 | +$11.40 |
| Q4 2025 | -$15.00 | +$9.90 |
| Q3 2025 | -$20.10 | -$0.68 |
| Q2 2025 | -$23.10 | -$1.28 |
| Q1 2025 | -$25.20 | -$5.18 |
| Q4 2024 | -$24.90 | -$6.00 |
NXL is still losing money, but far less than before: $13.63 per share over the past year, against $34.20 at its worst in late 2021.
NXL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $78.3K | +331% |
| Q2 2026 | $12.2K | -83% |
| Q1 2026 | $15K | -64% |
| Q4 2025 | $171.9K | +532% |
| Q3 2025 | $18.1K | -50% |
| Q2 2025 | $70.6K | +163% |
| Q1 2025 | $41K | -48% |
| Q4 2024 | $27.2K | +32% |
NXL's revenue is recovering but still below its 2022 peak: $78,301 last quarter, up 331% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3332% | +9592 points |
| Q2 2026 | -18480% | -16184 points |
| Q1 2026 | -14180% | -9276 points |
| Q4 2025 | -1404% | +9176 points |
| Q3 2025 | -12924% | -5962 points |
| Q2 2025 | -2296% | +2536 points |
| Q1 2025 | -4904% | -3539 points |
| Q4 2024 | -10579% | -2669 points |
NXL's operating margin was −3332% last quarter, up 9592 points from the same quarter a year ago.
NXL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6M | -$121.5K |
| Q2 2026 | -$1.8M | -$884.5K |
| Q1 2026 | -$1.7M | -$286.8K |
| Q4 2025 | -$1.1M | -$13.5K |
| Q3 2025 | -$1.5M | -$666K |
| Q2 2025 | -$917.2K | +$329.3K |
| Q1 2025 | -$1.4M | -$662.9K |
| Q4 2024 | -$1.1M | -$130.4K |
NXL has burned cash in almost every quarter: −$6M over the past year, against −$5M the year before.
NXL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +71.9K shares |
| 1 year | +48% | +253K shares |
| 3 years | +220% | +534K shares |
| 5 years | +376% | +613K shares |
NXL has 776,657 diluted shares, up 48% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
NXL Net Leverage
NXL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NXL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.1 | Oversold |
| Stochastic | 1.3 | Oversold |
NXL's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
NXL PE vs Healthcare Sector
NXL has no meaningful PE right now: it lost money over the past year.
NXL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.81 | 47% below |
| 20 week MA | $6.97 | 79% below |
| 50 week MA | $12.1 | 88% below |
| 100 week MA | $31.0 | 95% below |
| 200 week MA | $31.2 | 95% below |
NXL is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
NXL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $67.5 | $23.4 | -65% |
| 2023 | $23.4 | $12.1 | -48% |
| 2024 | $12.1 | $88.5 | +629% |
| 2025 | $88.5 | $18.9 | -79% |
| 2026 YTD | $18.9 | $1.49 | -92% |
NXL's yearly returns have swung widely, from +629% in 2024 to −79% in 2025. It's down 92% so far in 2026.